INVA
HealthcareInnoviva, Inc.
$20.03
+$0.16 (+0.81%)
Jan 5, 2026
Price History (1Y)
Analysis
Innoviva, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $1.50B and revenue of $388.52M (TTM). The company has a relatively small workforce of 127 employees. The company exhibits strong financial health, with high profitability margins: gross margin at 84.5%, operating margin at 35.3%, and profit margin at 32.8%. Additionally, Innoviva generates substantial returns on equity (15.2%) and assets (8.2%), indicating effective use of capital. The balance sheet is also in a relatively healthy position, with cash reserves of $533.10M and debt of $323.23M, translating to a debt-to-equity ratio of 32.01. In terms of valuation, Innoviva's forward P/E ratio stands at 9.84, which may be considered attractive relative to its revenue growth rate of 20.4% (YoY). The company's price to book and price to sales ratios are also lower than industry averages. However, dividend information is not available for analysis.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Innoviva, Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Visit website →Key Statistics
- Market Cap
- $1.50B
- P/E Ratio
- 12.07
- 52-Week High
- $22.76
- 52-Week Low
- $16.52
- Avg Volume
- 868.27K
- Beta
- 0.45
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 127